{"id":"W2918036803","doi":"10.21037/sci.2019.02.01","title":"Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?","year":2019,"lang":"en","type":"letter","venue":"Stem Cell Investigation","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"EMD Serono; Genentech; Sierra Oncology; Ipsen; Astex Pharmaceuticals; Exelixis; Daiichi-Sankyo; Pfizer; Eisai; Merck KGaA; Array BioPharma; AstraZeneca; Eli Lilly and Company","keywords":"Triple-negative breast cancer; Breast cancer; Medicine; Oncology; Estrogen receptor; Internal medicine; Progesterone receptor; Chemotherapy; Cancer; Estrogen; Epidermal growth factor receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001828926,0.0003955721,0.0008922772,0.0002847375,0.001238315,0.001512754,0.0008650672,0.01269743,0.004331496],"category_scores_gemma":[0.007125226,0.000253805,0.0005709994,0.0003717251,0.001802179,0.002530392,0.0006815877,0.01457858,0.003224747],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002368454,"about_ca_system_score_gemma":0.001515084,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000862422,"about_ca_topic_score_gemma":0.002250433,"domain_scores_codex":[0.9988623,0.0005002235,0.0001019558,0.0001203941,0.0003025865,0.0001126677],"domain_scores_gemma":[0.9959177,0.002591217,0.0002459453,0.0001619873,0.0005101629,0.0005728907],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002894956,0.0001242896,0.001403262,0.0002377348,0.00003074023,0.003816875,0.0001418671,0.0001793745,0.0009647309,0.007803698,0.8981698,0.08683807],"study_design_scores_gemma":[0.0002529034,0.0003088276,0.001874851,0.0005937496,0.00005384675,0.006204299,0.0003731426,0.0006431353,0.0006135385,0.0272987,0.9617329,0.00005014791],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0008890706,0.01012399,0.0002629138,0.9751806,0.01089263,0.00001659992,0.00003027417,0.00002605603,0.002577899],"genre_scores_gemma":[0.01437066,0.02161609,0.0009009771,0.8780472,0.07944173,0.0000801257,0.00004981508,0.00002283695,0.005470704],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.01269743,"threshold_uncertainty_score":0.01718438,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02515456554210938,"score_gpt":0.2617261301684112,"score_spread":0.2365715646263018,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}